<?xml version="1.0" encoding="UTF-8"?>
<ref id="ref29">
 <mixed-citation publication-type="journal" id="cit29">
  <name>
   <surname>Shamsi</surname>
   <given-names>A.</given-names>
  </name>; 
  <name>
   <surname>Mohammad</surname>
   <given-names>T.</given-names>
  </name>; 
  <name>
   <surname>Anwar</surname>
   <given-names>S.</given-names>
  </name>; 
  <name>
   <surname>AlAjmi</surname>
   <given-names>M. F.</given-names>
  </name>; 
  <name>
   <surname>Hussain</surname>
   <given-names>A.</given-names>
  </name>; 
  <name>
   <surname>Rehman</surname>
   <given-names>M. T.</given-names>
  </name>; 
  <name>
   <surname>Islam</surname>
   <given-names>A.</given-names>
  </name>; 
  <name>
   <surname>Hassan</surname>
   <given-names>M. I.</given-names>
  </name>
  <article-title>Glecaprevir and Maraviroc are high-affinity inhibitors of SARS-CoV-2 main protease: possible implication in COVID-19 therapy</article-title>. 
  <source>Biosci. Rep.</source>
  <year>2020</year>, 
  <volume>40</volume>, 
  <elocation-id>450</elocation-id>
  <pub-id pub-id-type="doi">10.1042/BSR20201256</pub-id>.
 </mixed-citation>
</ref>
